Mary L. Gemignani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mary L. Gemignani has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
Michelle Stempel
Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA
12 shared publicationsMonica Morrow
Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center , New York, New York , USA
12 shared publicationsEmily C. Zabor
Department of Quantitative Health Sciences, Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA
8 shared publicationsVaradan Sevilimedu
Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA
8 shared publicationsAngelena Crown
Breast Surgery, True Family Women’s Cancer Center, Swedish Cancer Institute, Seattle, USA
6 shared publicationsAnne Eaton
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
6 shared publications
Latest Publications
- 9 August 2023
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30 (12) , 7091-7098
Long-Term Patient-Reported Outcomes Comparing Oncoplastic Breast Surgery and Conventional Breast-Conserving Surgery: A Propensity Score-Matched Analysis
Oncoplastic breast surgery (OBS) combines plastic surgery techniques with conventional breast-conserving surgery (BCS) and expands BCS eligibility. Limited
- 9 August 2023
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30 (12) , 7091-7098
Long-Term Patient-Reported Outcomes Comparing Oncoplastic Breast Surgery and Conventional Breast-Conserving Surgery: A Propensity Score-Matched Analysis
Oncoplastic breast surgery (OBS) combines plastic surgery techniques with conventional breast-conserving surgery (BCS) and expands BCS eligibility. Limited
- 15 June 2023
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30 (9) , 5350-5351
ASO Visual Abstract: The Impact of Breast-Conserving Surgery Re-excision on Patient-Reported Outcomes Using the BREAST-Q
- 15 June 2023
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30 (9) , 5350-5351
ASO Visual Abstract: The Impact of Breast-Conserving Surgery Re-excision on Patient-Reported Outcomes Using the BREAST-Q
- 12 June 2023
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30 (9) , 5341-5349
The Impact of Breast-Conserving Surgery Re-excision on Patient-Reported Outcomes Using the BREAST-Q
Approximately 14% of women undergoing breast-conserving surgery (BCS) require re-excision to achieve negative margins following the Society of Surgical Onc
- 12 June 2023
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30 (9) , 5341-5349
The Impact of Breast-Conserving Surgery Re-excision on Patient-Reported Outcomes Using the BREAST-Q
Approximately 14% of women undergoing breast-conserving surgery (BCS) require re-excision to achieve negative margins following the Society of Surgical Onc
- 13 May 2023
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 110 (7) , 831-838
Strategies to avoid mastectomy skin-flap necrosis during nipple-sparing mastectomy
Nipple-sparing mastectomy is associated with a higher risk of mastectomy skin-flap necrosis than conventional skin-sparing mastectomy. There are limited prospective data examining modifiable intraoperative factors that contribute to skin-flap necrosis after nipple-sparing mastectomy. Data on consecutive patients undergoing nipple-sparing mastectomy between April 2018 and December 2020 were recorded prospectively. Relevant intraoperative variables were documented by both breast and plastic surgeons at the time of surgery. The presence and extent of nipple and/or skin-flap necrosis was documented at the first postoperative visit. Necrosis treatment and outcome was documented at 8–10 weeks after surgery. The association of clinical and intraoperative variables with nipple and skin-flap necrosis was analysed, and significant variables were included in a multivariable logistic regression analysis with backward selection. Some 299 patients underwent 515 nipple-sparing mastectomies (54.8 per cent (282 of 515) prophylactic, 45.2 per cent therapeutic). Overall, 23.3 per cent of breasts (120 of 515) developed nipple or skin-flap necrosis; 45.8 per cent of these (55 of 120) had nipple necrosis only. Among 120 breasts with necrosis, 22.5 per cent had superficial, 60.8 per cent had partial, and 16.7 per cent had full-thickness necrosis. On multivariable logistic regression analysis, significant modifiable intraoperative predictors of necrosis included sacrificing the second intercostal perforator (P = 0.006), greater tissue expander fill volume (P < 0.001), and non-lateral inframammary fold incision placement (P = 0.003). Modifiable intraoperative factors that may decrease the likelihood of necrosis after nipple-sparing mastectomy include incision placement in the lateral inframammary fold, preserving the second intercostal perforating vessel, and minimizing tissue expander fill volume.
- 13 May 2023
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 110 (7) , 831-838
Strategies to avoid mastectomy skin-flap necrosis during nipple-sparing mastectomy
Nipple-sparing mastectomy is associated with a higher risk of mastectomy skin-flap necrosis than conventional skin-sparing mastectomy. There are limited prospective data examining modifiable intraoperative factors that contribute to skin-flap necrosis after nipple-sparing mastectomy. Data on consecutive patients undergoing nipple-sparing mastectomy between April 2018 and December 2020 were recorded prospectively. Relevant intraoperative variables were documented by both breast and plastic surgeons at the time of surgery. The presence and extent of nipple and/or skin-flap necrosis was documented at the first postoperative visit. Necrosis treatment and outcome was documented at 8–10 weeks after surgery. The association of clinical and intraoperative variables with nipple and skin-flap necrosis was analysed, and significant variables were included in a multivariable logistic regression analysis with backward selection. Some 299 patients underwent 515 nipple-sparing mastectomies (54.8 per cent (282 of 515) prophylactic, 45.2 per cent therapeutic). Overall, 23.3 per cent of breasts (120 of 515) developed nipple or skin-flap necrosis; 45.8 per cent of these (55 of 120) had nipple necrosis only. Among 120 breasts with necrosis, 22.5 per cent had superficial, 60.8 per cent had partial, and 16.7 per cent had full-thickness necrosis. On multivariable logistic regression analysis, significant modifiable intraoperative predictors of necrosis included sacrificing the second intercostal perforator (P = 0.006), greater tissue expander fill volume (P < 0.001), and non-lateral inframammary fold incision placement (P = 0.003). Modifiable intraoperative factors that may decrease the likelihood of necrosis after nipple-sparing mastectomy include incision placement in the lateral inframammary fold, preserving the second intercostal perforating vessel, and minimizing tissue expander fill volume.
- 20 January 2023
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 198 (2) , 283-294
Pregnancy-associated breast cancer: does timing of presentation affect outcome?
Purpose Pregnancy-associated breast cancer (PABC) comprises breast cancer diagnosed during the gestational period or within 12 months postpartum. While the incidence of PABC appears to be increasing, data regarding prognosis remain limited. Methods Here we evaluate clinicopathologic features, treatments, and clinical outcomes among women with stage 0-III PABC diagnosed between 1992 and 2020. Comparisons were made between women who were diagnosed with PABC during gestation and those who were diagnosed within 12 months postpartum. Results A total of 341 women were identified, with a median age of 36 years (range 25–46). The pregnancy group comprised 119 (35%) women, while 222 (65%) women made up the postpartum group. Clinicopathologic features were similar between groups, with most patients being parous and presenting with stage I and II disease. Treatment delays were uncommon, with a median time from histologic diagnosis to treatment of 4 weeks for both groups. Recurrence-free survival was similar between groups: 67% at 10 years for both. While 10-year overall survival appeared higher in the postpartum group (83% versus 78%, p = 0.02), only the presence of nodal metastases was associated with an increased risk of death (hazard ratio 5.61, 95% CI 2.20–14.3, p < 0.001), whereas timing of diagnosis and receptor profile did not reach statistical significance. Conclusion Clinicopathologic features of women with PABC are similar regardless of timing of diagnosis. While 10-year recurrence-free survival is similar between groups, 10-year overall survival is higher among women diagnosed postpartum; however, timing of diagnosis may not be the driving factor in determining survival outcomes.
- 20 January 2023
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 198 (2) , 283-294
Pregnancy-associated breast cancer: does timing of presentation affect outcome?
Purpose Pregnancy-associated breast cancer (PABC) comprises breast cancer diagnosed during the gestational period or within 12 months postpartum. While the incidence of PABC appears to be increasing, data regarding prognosis remain limited. Methods Here we evaluate clinicopathologic features, treatments, and clinical outcomes among women with stage 0-III PABC diagnosed between 1992 and 2020. Comparisons were made between women who were diagnosed with PABC during gestation and those who were diagnosed within 12 months postpartum. Results A total of 341 women were identified, with a median age of 36 years (range 25–46). The pregnancy group comprised 119 (35%) women, while 222 (65%) women made up the postpartum group. Clinicopathologic features were similar between groups, with most patients being parous and presenting with stage I and II disease. Treatment delays were uncommon, with a median time from histologic diagnosis to treatment of 4 weeks for both groups. Recurrence-free survival was similar between groups: 67% at 10 years for both. While 10-year overall survival appeared higher in the postpartum group (83% versus 78%, p = 0.02), only the presence of nodal metastases was associated with an increased risk of death (hazard ratio 5.61, 95% CI 2.20–14.3, p < 0.001), whereas timing of diagnosis and receptor profile did not reach statistical significance. Conclusion Clinicopathologic features of women with PABC are similar regardless of timing of diagnosis. While 10-year recurrence-free survival is similar between groups, 10-year overall survival is higher among women diagnosed postpartum; however, timing of diagnosis may not be the driving factor in determining survival outcomes.
- 17 November 2022
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 197 (2) , 417-423
Do non-classic invasive lobular carcinomas derive a benefit from neoadjuvant chemotherapy?
Purpose Invasive lobular breast cancers (ILCs) respond poorly to neoadjuvant chemotherapy (NAC). The degree of benefit of NAC among non-classic ILC (NC-ILC) variants compared with classic ILCs (C-ILCs) is unknown. Methods Consecutive patients with Stage I-III ILC treated from 2003 to 2019 with NAC and surgery were identified, and grouped as C-ILC or NC-ILC as per the original surgical pathology report, with pathologist (A.G.) review performed if original categorization was unclear. A subset of similarly treated invasive ductal cancers (IDCs) was identified for comparison. Clinicopathologic characteristics and pathologic complete response (pCR) rates were evaluated. Results Of 145 patients with ILC, 101 (70%) were C-ILC and 44 (30%) were NC-ILC (IDC cohort: 1157 patients). ILC patients were older, more often cT3/T4 and cN2/N3, and less often high-grade compared to IDC patients. Those with NC-ILC were less often ER+/HER2− (55% versus 93%), and more often HER2 + (25% versus 7%) and TN (21% versus 0%, all p < 0.001). Breast pCR was more common among NC-ILC, but most frequent in IDC. Nodal pCR rates were also lowest among C-ILC patients, but similar among NC-ILC and IDC patients. On multivariable analysis, C-ILC (OR 0.09) and LVI (OR 0.51) were predictive of lack of breast pCR; non-ER+/HER2− subtypes and breast pCR were predictive of nodal pCR. When our analysis was repeated with patients stratified by receptor subtype, histology was not independently predictive of either breast or nodal pCR. Conclusion NC-ILC patients were significantly more likely to achieve breast and nodal pCR compared with C-ILC patients, but when stratified by subtype, histology was not independently predictive of breast or nodal pCR.
- 17 November 2022
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 197 (2) , 417-423
Do non-classic invasive lobular carcinomas derive a benefit from neoadjuvant chemotherapy?
Purpose Invasive lobular breast cancers (ILCs) respond poorly to neoadjuvant chemotherapy (NAC). The degree of benefit of NAC among non-classic ILC (NC-ILC) variants compared with classic ILCs (C-ILCs) is unknown. Methods Consecutive patients with Stage I-III ILC treated from 2003 to 2019 with NAC and surgery were identified, and grouped as C-ILC or NC-ILC as per the original surgical pathology report, with pathologist (A.G.) review performed if original categorization was unclear. A subset of similarly treated invasive ductal cancers (IDCs) was identified for comparison. Clinicopathologic characteristics and pathologic complete response (pCR) rates were evaluated. Results Of 145 patients with ILC, 101 (70%) were C-ILC and 44 (30%) were NC-ILC (IDC cohort: 1157 patients). ILC patients were older, more often cT3/T4 and cN2/N3, and less often high-grade compared to IDC patients. Those with NC-ILC were less often ER+/HER2− (55% versus 93%), and more often HER2 + (25% versus 7%) and TN (21% versus 0%, all p < 0.001). Breast pCR was more common among NC-ILC, but most frequent in IDC. Nodal pCR rates were also lowest among C-ILC patients, but similar among NC-ILC and IDC patients. On multivariable analysis, C-ILC (OR 0.09) and LVI (OR 0.51) were predictive of lack of breast pCR; non-ER+/HER2− subtypes and breast pCR were predictive of nodal pCR. When our analysis was repeated with patients stratified by receptor subtype, histology was not independently predictive of either breast or nodal pCR. Conclusion NC-ILC patients were significantly more likely to achieve breast and nodal pCR compared with C-ILC patients, but when stratified by subtype, histology was not independently predictive of breast or nodal pCR.
- 30 June 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 29 (9) , 1-2
ASO Author Reflections: Oncologic Safety of Fertility Preservation
- 30 June 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 29 (9) , 1-2
ASO Author Reflections: Oncologic Safety of Fertility Preservation
- 7 June 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 29 (9) , 5786-5796
Fertility Preservation in Young Women with Breast Cancer: Impact on Treatment and Outcomes
The impact of chemotherapy timing on the fertility preservation (FP) decision is poorly understood. Here we evaluate factors associated with FP completion
- 7 June 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 29 (9) , 5786-5796
Fertility Preservation in Young Women with Breast Cancer: Impact on Treatment and Outcomes
The impact of chemotherapy timing on the fertility preservation (FP) decision is poorly understood. Here we evaluate factors associated with FP completion
- 1 March 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 29 (3) , 1703-1704
ASO Author Reflections: Stage IV Pregnancy-Associated Breast Cancer: A Continuum of Disease
- 1 March 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 29 (3) , 1703-1704
ASO Author Reflections: Stage IV Pregnancy-Associated Breast Cancer: A Continuum of Disease